Neuication Template fiom ATI

Medication: ASA 81mg C C ually uo noL CrushASA class Sallcyllc acld

\ected Pbarmacological action lnhlblLs prosLaglandln synLhesls resulLlng ln analgesla
(Lhe rellef of paln) anLllnflammaLory acLlvlLy and plaLeleL aggregaLlon (def parL of Lhe whole)
lnhlblLlon reduces fever by acLlng on Lhe bralns heaLregulaLlng cenLer Lo promoLe vasodllaLaLlon and
sweaLlng ** ln oLher words you would expecL Lhls medlcaLlon Lo decrease Lhe cloLLlng facLor and Lhe
paLlenL would Lake longer Lo cloL
Tbera\eutic Uses: 1reaLmenL of mlld Lo moderaLe paln fever varlous lnflammaLory condlLlons
reducLlon of rlsk of deaLh or Ml ln paLlenLs wlLh prevlous lnfarcLlon or unsLable anglna pecLorls or
recurrenL LranslenL lschemla aLLacks (1lAs) or sLroke ln men who have had LranslenL braln lschemla
caused by plaLeleL emboll
SideJAdverse XXects dlzzlness confuslon LlnnlLus hearlng loss prolonged bleedlng Llme
easy brulslng lmpalred renal funcLlon (p 131 earson urug Culde)
FoodJMedication Interactions: A|coho| May lncrease rlsk of Cl ulceraLlon and prolong
bleedlng Llme
Antac|ds cort|costero|ds ur|nary a|ka||n|zers May decrease asplrln levels
Carbon|c anhydrase |nh|b|tors (eg acetohexam|de) methotrexate va|pro|c ac|d
May increase levels oI these drugs.
epar|n ora| ant|coagu|ants May lncrease rlsk of bleedlng
nsu||n su|fony|ureas Asplrln (more Lhan 2rg/day) may poLenLlaLe glucose lowerlng
robenec|d su|f|npyrazone May decrease urlcosurlc effecL
ConLralndlcaLlons lnclude PypersenslLlvlLy Lo sallcylaLes or nSAlus hemophllla bleedlng ulcers or
hemorrhaglc sLaLes Adverse 8eacLlons
LLn1 ulzzlness LlnnlLus
Cl 8leedlng dyspepsla hearLburn nausea
PemaLologlc Anemla decreased lron concenLraLlon lncreased bleedlng Llmes
Mlscellaneous
PypersenslLlvlLy reacLlons may lnclude urLlcarla hlves rashes angloedema and anaphylacLlc shock
O nurslng lnLervenLlons/CllenL 1eachlng nstruct patient to take drug with Iood or aIter meals
and with Iull glass oI water. Advise patient to avoid antacids within 1 to 2 h aIter
ingestion oI enteric-coated tablets.
O %ell patient to discard any aspirin that has a vinegar-like odor.
O nstruct patient to report ringing in ears or unusual bleeding, bruising, or persistent G
pain.
O Advise patient on long-term therapy to inIorm health care provider or dentist beIore
seeking surgery or dental care.
O %ell patient on sodium-restricted diet to limit use oI eIIervescent or buIIered aspirin
preparations.
O aution parents to avoid giving aspirin to children or teenagers with Ilu-like symptoms or
chickenpox without Iirst consulting health care provider.
O nstruct patient to avoid intake oI alcoholic beverages or other $ depressants.
ursing Administration: MonlLor for loss of Lolerance of ASA lncludlng nausea vomlLlng
lnLesLlnal cramps MonlLor for fullness ln Lhe ears rlnglng ln Lhe ears AdmlnlsLraLlon ls C and 8
330630mg for an adulL
valuation oX Medication XXectiveness: no adverse or slde effecLs of Lhe medlcaLlon
CllenL LoleraLed well wlLh no adverse effecLs uecrease ln lnflammaLlon and mlld paln